These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 3104115)

  • 1. Characteristics of two types of meningococcal group C polysaccharide conjugates using tetanus toxoid as carrier protein.
    Beuvery EC; Roy R; Kanhai V; Jennings HJ
    Dev Biol Stand; 1986; 65():197-204. PubMed ID: 3104115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytical, toxicological and immunological consequences of the use of N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide as coupling reagent for the preparation of meningococcal group C polysaccharide-tetanus toxoid conjugate as vaccine for human use.
    Beuvery EC; Speijers GJ; Lutz BI; Freudenthal D; Kanhai V; Haagmans B; Derks HJ
    Dev Biol Stand; 1986; 63():117-28. PubMed ID: 3091432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates.
    Jennings HJ; Lugowski C
    J Immunol; 1981 Sep; 127(3):1011-8. PubMed ID: 6790606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine.
    Jennings HJ; Roy R; Gamian A
    J Immunol; 1986 Sep; 137(5):1708-13. PubMed ID: 3091688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New meningococcal C polysaccharide-tetanus toxoid conjugate Physico-chemical and immunological characterization.
    Cuello M; Cabrera O; Martinez I; Del Campo JM; Camaraza MA; Sotolongo F; Pérez O; Sierra G
    Vaccine; 2007 Feb; 25(10):1798-805. PubMed ID: 17240485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide.
    Gudlavalleti SK; Lee CH; Norris SE; Paul-Satyaseela M; Vann WF; Frasch CE
    Vaccine; 2007 Nov; 25(46):7972-80. PubMed ID: 17936445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicochemical and immunological characterization of meningococcal group A polysaccharide-tetanus toxoid conjugates prepared by two methods.
    Beuvery EC; vd Kaaden A; Kanhai V; Leussink AB
    Vaccine; 1983 Dec; 1(1):31-6. PubMed ID: 6442499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and immunochemical characterization of meningococcal group C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines.
    Beuvery EC; Miedema F; van Delft R; Haverkamp J
    Infect Immun; 1983 Apr; 40(1):39-45. PubMed ID: 6187693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
    Jennings HJ
    Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499
    [No Abstract]   [Full Text] [Related]  

  • 10. A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants.
    Nolan T; Lambert S; Roberton D; Marshall H; Richmond P; Streeton C; Poolman J; Boutriau D
    Vaccine; 2007 Dec; 25(51):8487-99. PubMed ID: 17996996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological evaluation of meningococcal group C polysaccharide-tetanus toxoid conjugate in mice.
    Beuvery EC; van Delft RW; Miedema F; Kanhai V; Nagel J
    Infect Immun; 1983 Aug; 41(2):609-17. PubMed ID: 6409811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice.
    Peeters CC; Tenbergen-Meekes AM; Evenberg DE; Poolman JT; Zegers BJ; Rijkers GT
    J Immunol; 1991 Jun; 146(12):4308-14. PubMed ID: 2040803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine potential of meningococcal group C polysaccharide-tetanus toxoid conjugate.
    Beuvery EC; Miedema F; van Delft RW; Haverkamp J; Tiesjema RH; Nagel J
    J Infect; 1983 May; 6(3):247-55. PubMed ID: 6411824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.
    Baker CJ; Paoletti LC; Wessels MR; Guttormsen HK; Rench MA; Hickman ME; Kasper DL
    J Infect Dis; 1999 Jan; 179(1):142-50. PubMed ID: 9841833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.
    Southern J; Deane S; Ashton L; Borrow R; Goldblatt D; Andrews N; Balmer P; Morris R; Kroll JS; Miller E
    Clin Diagn Lab Immunol; 2004 Nov; 11(6):1100-4. PubMed ID: 15539513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of conjugation methodology on the immunogenicity and protective efficacy of meningococcal group C polysaccharide-P64k protein conjugates.
    Carmenate T; Canaán L; Alvarez A; Delgado M; González S; Menéndez T; Rodés L; Guillén G
    FEMS Immunol Med Microbiol; 2004 Apr; 40(3):193-9. PubMed ID: 15039094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa.
    Lee CH; Kuo WC; Beri S; Kapre S; Joshi JS; Bouveret N; LaForce FM; Frasch CE
    Vaccine; 2009 Jan; 27(5):726-32. PubMed ID: 19063929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vaccines against Neisseria meningitidis].
    Ferrón L; Criado MT; Ferreirós CM
    Enferm Infecc Microbiol Clin; 1992 May; 10(5):296-301. PubMed ID: 1391002
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide.
    Bartoloni A; Norelli F; Ceccarini C; Rappuoli R; Costantino P
    Vaccine; 1995 Apr; 13(5):463-70. PubMed ID: 7543714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary trends in conjugate vaccine development.
    Cruse JM; Lewis RE
    Contrib Microbiol Immunol; 1989; 10():1-10. PubMed ID: 2510970
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.